Welcome to our dedicated page for Polyrizon SEC filings (Ticker: PLRZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Polyrizon Ltd. (PLRZ) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Polyrizon files reports on Form 20-F and Form 6-K under the Securities Exchange Act of 1934, and these documents offer insight into its development-stage biotechnology activities, financial condition, and corporate actions.
Recent Form 6-K filings incorporate press releases on key scientific and product milestones, such as preclinical results for PL-14 Allergy Blocker and PL-16 Viral Blocker, as well as data from the company’s intranasal naloxone hydrogel program within the Trap & Target™ platform. Other 6-K submissions include interim condensed financial statements, management’s discussion and analysis, and notices related to shareholder meetings and voting matters.
Filings also document capital structure and listing-related events. For example, Polyrizon has reported a reverse share split of its ordinary shares at a 1-for-6 ratio and has furnished a press release noting that it regained compliance with Nasdaq listing requirements. These disclosures help investors understand changes in share count, adjustments to warrants and options, and the company’s listing status.
Through Stock Titan, users can review Polyrizon’s 6-K reports and related exhibits, including financial statements, regulatory correspondence summaries, and scientific press releases that are incorporated by reference into registration statements on Form S-8 and Form F-3. AI-powered tools on the platform can assist in summarizing lengthy filings, highlighting key sections on topics such as product development, regulatory interactions with the FDA, and corporate approvals, helping readers navigate Polyrizon’s SEC reporting history more efficiently.
Polyrizon Ltd. filed a Form 6-K to share that it has submitted amended claims in its U.S. patent application covering its proprietary intranasal drug delivery platform. The new claims extend protection from the core mucoadhesive composition to related drug delivery systems and methods of use.
The expanded claim set focuses on compositions with sulfated polysaccharide polymers and additional polymers that form a continuous film on epithelial mucosa, aiming to improve delivery of active pharmaceutical ingredients. This step supports Polyrizon’s strategy to strengthen its global intellectual property around its intranasal hydrogel technologies, including its Capture and Contain and Trap and Target platforms.
Polyrizon Ltd. filed Amendment No. 1 to its Form F-1 registration statement to include a conformed signature for the independent auditor's consent and to update Part II (signatures and exhibit index). The prospectus (Part I) is unchanged.
The amendment is an exhibits-only filing and does not amend offering terms; it also discloses recent unregistered issuances and warrant/exercise activity, including private placements and registered direct offerings described in Part II.
Polyrizon Ltd. reports passive beneficial ownership disclosures from MMCAP International Inc. SPC and MM Asset Management Inc. The joint filing shows beneficial ownership increased to 136,525 ordinary shares as of 04/24/2026 (representing 7.3% of the class). The filing also reports the prior position of 100,247 shares as of 04/21/2026 (6.2%). The registrants state they hold shared voting and dispositive power over the disclosed shares and the filing is signed under a joint filing agreement.
Polyrizon Ltd. filed a divisional European patent application for its Trap & Target (T&T) intranasal drug delivery platform, aiming to protect its advanced hydrogel-based system that prolongs drug residence time and contact with nasal mucosa.
The filing aligns with a recently announced U.S. patent application covering Polyrizon’s two core technologies: Capture and Contain (C&C™), a nasal barrier against airborne biological threats, and T&T™, focused on enhancing bioavailability for local and systemic delivery of active pharmaceutical ingredients.
Polyrizon Ltd. files a Form F-1 to register for resale up to 499,999 ordinary shares by a selling shareholder, consisting of shares issuable upon exercise of PIPE pre-funded warrants (up to 111,111 shares) and ordinary share warrants (up to 388,888 shares).
The resale registration covers only shares held by the identified Selling Shareholder; Polyrizon will not receive proceeds from resale but may receive up to approximately $3.5 million if the warrants are exercised for cash (exercise prices: $9.00 for ordinary share warrants and $0.00001 for pre-funded warrants). Shares outstanding were 1,871,848 as of April 22, 2026; pro forma outstanding assuming full exercise would be 2,371,847.
Polyrizon Ltd. entered into definitive agreements for a registered direct offering and concurrent private placement expected to raise approximately $3.5 million in gross proceeds. The structure combines ordinary shares, low-priced pre-funded warrants, and five-year common warrants priced through units at $9.00 per unit.
The company will sell 87,777 ordinary shares and 190,000 pre-funded warrants in the registered direct deal, plus 111,111 PIPE pre-funded warrants and 388,888 common warrants in the private placement. Following completion and full exercise of all pre-funded warrants, Polyrizon expects to have 2,083,939 ordinary shares outstanding and plans to use the net proceeds for general corporate purposes and working capital.
Polyrizon Ltd. is registering 87,777 Ordinary Shares and 190,000 Pre-Funded Warrants (each exercisable for one Ordinary Share) at $9.00 per Ordinary Share and $8.99999 per Pre-Funded Warrant, respectively. The offering includes the Ordinary Shares issuable upon exercise of the Pre-Funded Warrants. Delivery is expected on or about April 8, 2026.
There is a concurrent private placement of 111,111 PIPE Pre-Funded Warrants and 388,888 unregistered Ordinary Share Warrants (exercise price $9.00; five-year term). Proceeds before expenses for the registered portion are approximately $2.499,991.10 with estimated net proceeds combined from the offering and concurrent private placement of approximately $3.1M. Ordinary Shares outstanding prior to the offering were 1,695,051, rising to 1,972,828 assuming full exercise of the Registered Pre-Funded Warrants.
Polyrizon Ltd. Chief Executive Officer Tomer Izraeli sold 500 ordinary shares in an open-market transaction at $11.85 per share. Following the sale, he directly holds 31,512 ordinary shares.
These holdings consist of 6,459 ordinary shares, 53 restricted ordinary shares that vest monthly, and 25,000 restricted ordinary shares that vest quarterly, each vesting schedule being subject to his continued service.
Polyrizon Ltd. director Carmel Liron reported an open-market sale of 942 Ordinary Shares at $12.36 per share. After this transaction, Liron directly holds 3,127 Ordinary Shares. These holdings consist of 521 ordinary shares and 2,606 restricted ordinary shares that vest in equal quarterly installments, subject to continued service.